Abcentra

Abcentra is a clinical-stage biopharmaceutical company based in Los Angeles, California, focused on preventing heart attacks in patients with coronary artery disease (CAD). The company describes itself as being on a mission to prevent heart attacks, and its scientific premise is that inflammation — specifically vascular inflammation driven by oxidized low-density lipoprotein (OxLDL) and pro-inflammatory plaque macrophages — is a major driver of heart attacks in CAD patients. Rather than suppressing inflammation systemically, Abcentra is pursuing a plaque-targeted approach intended to intervene with precision, maximizing potential benefit while minimizing treatment-associated risks. The company's lead clinical-stage product is Orticumab, described as a first-in-class, fully human monoclonal antibody against oxidized LDL that targets vascular inflammation locally. According to the company, Orticumab binds oxidized LDL with modified ApoB, complexes with it, and inhibits the pro-inflammatory activity of plaque macrophages by activating an inhibitory cell surface receptor (Fcγ receptor II), thereby down-regulating NF-kB. The intended effect is a reduction in plaque inflammation, vulnerability, and size. Abcentra states that Orticumab has demonstrated the potential to reduce coronary inflammation in a phase 2a study, and that it is being developed for secondary prevention after an acute coronary syndrome (ACS), with further plans to expand use into CAD patients with elevated coronary inflammation. Abcentra frames its work around the scale of the CAD problem. It cites coronary artery disease as the leading cause of death worldwide and notes that CAD affects more than 20.5 million adults in the U.S. alone. It also highlights that inflammation and oxidative stress spike after an ACS event, that risk of a second heart attack or death is significantly higher after ACS, and that despite therapeutic advances, roughly one in five patients will experience a recurrent heart attack or die within two years of the initial ACS event even on optimal preventive therapy. The company points to the Fat Attenuation Index (FAI) score, a precision imaging biomarker derived from CCTA that quantifies coronary inflammation and is predictive of major adverse cardiovascular events, as a way to measure coronary inflammation for the first time. Abcentra's leadership team is presented as combining expertise in science, medicine, and business. Named leaders include Chris Farina, M.S., RAC, Chief Executive Officer; Jan Nilsson, M.D., PhD, Chief Scientific Officer and Board Member; Kevin Melvin, BS, CMP, Vice President, Clinical Operations; and Todd C. Villines, MD, FACC, FAHA, MSCCT, Executive Medical Director. The company maintains a pipeline page and a news and insights section on its website. It is a privately held company; no parent company, ownership group, or public listing is indicated in the available evidence.

Abcentra is a clinical-stage biopharmaceutical company located in Los Angeles, California, in the United States. Publicly available information about the company is centered on its scientific program and its lead therapeutic candidate rather than on a long corporate chronology, and the available evidence does not specify a founding year or founder. The company's stated mission is to prevent heart attacks. Its scientific foundation rests on the long-recognized role of inflammation in coronary artery disease: for decades cardiologists have known that inflammation plays a key role in the development of CAD and causes heart attacks, and systemic anti-inflammatory treatments can help but carry other potential serious risks and side effects. Abcentra's approach is to intervene locally and with precision, targeting vascular inflammation rather than suppressing inflammation throughout the body. The central expression of that strategy is Orticumab, which Abcentra describes as a first-in-class, fully human monoclonal antibody against oxidized LDL that targets vascular inflammation locally. Mechanistically, the company states that Orticumab specifically binds oxidized LDL with modified ApoB, complexes with it, and inhibits the pro-inflammatory activity of plaque macrophages by activating an inhibitory cell surface receptor (Fcγ receptor II), thereby down-regulating NF-kB. The intended result is a reduction in plaque inflammation, vulnerability, and size. Abcentra reports that Orticumab has demonstrated the potential to reduce coronary inflammation in a phase 2a study, and that it is developing the drug for secondary prevention after an acute coronary syndrome (ACS), with further plans to expand use into coronary artery disease patients with elevated coronary inflammation. Abcentra situates its program within the epidemiology of CAD and ACS. It notes that CAD is the leading cause of death worldwide and affects more than 20.5 million adults in the U.S. alone, and that ACS presents clinically as heart attack or unstable angina. The company emphasizes that inflammation and oxidative stress spike after an ACS event, that risk of a second heart attack or death is significantly higher afterward, and that despite therapeutic advances roughly one in five patients will experience a recurrent heart attack or die within two years of the initial ACS event even on optimal preventive therapy. It also highlights the Fat Attenuation Index (FAI) score, a precision imaging biomarker derived from CCTA that quantifies coronary inflammation and is highly predictive of cardiac events, as a means of measuring coronary inflammation for the first time. Abcentra's leadership team is composed of professionals with expertise in science, medicine, and business. Named leaders include Chris Farina, M.S., RAC, Chief Executive Officer; Jan Nilsson, M.D., PhD, Chief Scientific Officer and Board Member; Kevin Melvin, BS, CMP, Vice President, Clinical Operations; and Todd C. Villines, MD, FACC, FAHA, MSCCT, Executive Medical Director. The company maintains a pipeline page and a news and insights section on its website. It is privately held, and the available evidence does not identify a parent company, ownership group, or public listing.

• Orticumab demonstrated the potential to reduce coronary inflammation in a phase 2a study, according to the company.

Clinical-stage biopharmaceutical company pioneering plaque-targeted, oxidized LDL inhibition to prevent heart attacks in coronary artery disease patients.

• Orticumab

  A first-in-class, fully human monoclonal antibody against oxidized LDL that targets vascular inflammation locally; developed for secondary prevention after acute coronary syndrome, with plans to expand into coronary artery disease patients with elevated coronary inflammation.

• 2020-08-26

  Abcentra appoints Timothy Wright to its board[6]Abcentra任命Timothy Wright为董事会成员prnewswire.com

  Reported: 2020-08-26

  Abcentra announced that Timothy Wright had joined the company's board of directors.

1. 1Home - Abcentraabcentra.com
2. 2Orticumab - Abcentraabcentra.com
3. 3Our Company - Abcentraabcentra.com
4. 4Coronary Artery Disease - Abcentraabcentra.com
5. 5Abcentra (United States) - Wikidatawikidata.org
6. 6Abcentra任命Timothy Wright为董事会成员prnewswire.com
7. 7Abcentra Appoints Entrepreneur and Cardiologist Michael H. Davidson to Board of Directorsprnewswire.com